#1 Clinical Trials Search in Europe

Ganirelix

Ganirelix, a gonadotropin-releasing hormone (GnRH) antagonist, is being extensively studied in clinical trials for its potential in improving fertility treatments and regulating hormones. This article explores the various applications of Ganirelix in controlled ovarian stimulation, in vitro fertilization (IVF), and hormone-related conditions, highlighting its role in enhancing reproductive outcomes and managing hormonal imbalances.

Table of Contents

What is Ganirelix?

Ganirelix is a medication used in reproductive medicine, particularly in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). It belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) antagonists[1]. Ganirelix is also known by several other names, including:

  • Orgalutran®
  • Org 37462
  • SCH 900761
  • Ganirelix Acetate
  • Ganirest

These alternative names may be used interchangeably in medical settings or on prescription labels[1].

How Ganirelix Works

Ganirelix works by preventing premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation (COS) for ART procedures[5]. LH is a hormone that plays a crucial role in ovulation. In natural menstrual cycles, a surge in LH triggers the release of mature eggs from the ovaries. However, during fertility treatments, it’s important to control when ovulation occurs to optimize the chances of successful egg retrieval.

By blocking the action of GnRH, Ganirelix prevents the pituitary gland from releasing LH, thus allowing doctors to have better control over the timing of ovulation[1]. This helps ensure that eggs are retrieved at the optimal time for fertilization and embryo development.

Medical Uses of Ganirelix

Ganirelix is primarily used in the following medical contexts:

  1. Controlled Ovarian Stimulation (COS): Ganirelix is used to prevent premature LH surges in women undergoing COS for IVF or ICSI[5].
  2. In Vitro Fertilization (IVF): It’s an integral part of many IVF protocols, helping to improve the timing and success of egg retrieval[7].
  3. Intracytoplasmic Sperm Injection (ICSI): Similar to its use in IVF, Ganirelix helps control ovulation timing in ICSI procedures[10].
  4. Polycystic Ovary Syndrome (PCOS): Some research is exploring the use of low-dose Ganirelix to help regulate hormone levels in women with PCOS[2].

How Ganirelix is Administered

Ganirelix is typically administered as a subcutaneous (under the skin) injection. The most common dosage is 0.25 mg per day, usually starting on day 5 or 6 of ovarian stimulation and continuing until the day of human chorionic gonadotropin (hCG) administration[1][4]. However, the exact timing and duration of treatment can vary depending on individual patient factors and the specific fertility treatment protocol being used.

In some cases, different dosages or administration schedules may be used. For example, one study explored using Ganirelix at 0.125 mg, 0.25 mg, and 0.5 mg doses[1]. Another study investigated the use of very low doses (0.0625 mg and 0.025 mg) in women with PCOS[2].

Effectiveness of Ganirelix

Ganirelix has been shown to be effective in preventing premature LH surges and improving outcomes in assisted reproduction techniques. Some key measures of its effectiveness include:

  • Number of oocytes retrieved: This is often used as a primary measure of effectiveness in fertility treatments. Studies have shown that Ganirelix treatment results in a satisfactory number of retrieved oocytes[4][10].
  • Fertilization rate: This refers to the percentage of retrieved eggs that are successfully fertilized. Ganirelix treatment has been associated with good fertilization rates[10].
  • Pregnancy rates: Studies have reported positive pregnancy outcomes with Ganirelix treatment, including chemical pregnancy rates (early pregnancy detected by hormone levels) and clinical pregnancy rates (pregnancy confirmed by ultrasound)[10].

Potential Side Effects

Like all medications, Ganirelix can potentially cause side effects. However, it’s generally well-tolerated. Common side effects may include:

  • Injection site reactions (redness, swelling, or itching at the injection site)
  • Headache
  • Nausea
  • Abdominal discomfort

More serious side effects are rare but can occur. It’s important to discuss potential risks and side effects with your healthcare provider before starting treatment[5].

Ongoing Research and Future Prospects

Research into new applications and optimized protocols for Ganirelix is ongoing. Some areas of current investigation include:

  • Use in PCOS: Researchers are exploring whether low-dose Ganirelix can help regulate hormone levels in women with PCOS[2].
  • Early follicular phase administration: Some studies are investigating whether starting Ganirelix earlier in the menstrual cycle could improve outcomes[9].
  • Oral alternatives: Research is being conducted on oral medications that could potentially replace injectable GnRH antagonists like Ganirelix[10].

As research continues, our understanding of how best to use Ganirelix in fertility treatments may evolve, potentially leading to improved success rates and patient experiences.

Aspect Details
Primary Uses Controlled ovarian stimulation, IVF, PCOS treatment
Dosage Range 0.025 mg to 0.5 mg daily (subcutaneous injection)
Key Outcomes Measured Number of oocytes retrieved, fertilization rates, pregnancy rates
Potential Benefits Improved oocyte quality, better control of ovulation, increased fertilization rates
Ongoing Research Areas Optimal dosing, timing of administration, use in various reproductive conditions

FAQ

  • What is Ganirelix and how does it work? Ganirelix is a GnRH antagonist that works by blocking GnRH receptors in the pituitary gland. This action prevents premature luteinizing hormone (LH) surges during fertility treatments, allowing for better control of the ovulation process.
  • In which medical conditions is Ganirelix being studied? Ganirelix is primarily studied in controlled ovarian stimulation for IVF, but it's also being investigated for its potential in treating polycystic ovary syndrome (PCOS) and regulating hormone levels in various reproductive health conditions.
  • How is Ganirelix administered in clinical trials? In most trials, Ganirelix is administered as a subcutaneous injection, with doses typically ranging from 0.025 mg to 0.5 mg daily. The duration and timing of administration vary depending on the specific study protocol and treatment purpose.
  • What are the potential benefits of using Ganirelix in fertility treatments? Potential benefits include improved control of the ovulation process, better oocyte maturation and quality, increased fertilization rates, and potentially higher pregnancy rates in assisted reproductive techniques.
  • Are there any side effects associated with Ganirelix use in clinical trials? While specific side effects are not detailed in the provided trial information, GnRH antagonists like Ganirelix are generally well-tolerated. Common side effects may include injection site reactions, headache, and nausea. Always consult with a healthcare provider for a complete list of potential side effects.

Ongoing Clinical Trials on Ganirelix

  • Study of Semaglutide on Embryo Quality in Overweight and Obese Women Undergoing In Vitro Fertilization for Infertility

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Progesterone and Ganirelix for Preventing LH Surge in Women Undergoing Ovarian Stimulation for Egg Donation

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Medroxyprogesterone Acetate and Ganirelix for Women Undergoing Fertility Treatment with Embryo Accumulation

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Corifollitropin Alfa and Modified Natural Cycles for Women with Subfertility and Low Ovarian Response

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study Comparing Corifollitropin Alfa and Progestin Primed Ovarian Stimulation for Women with Subfertility Undergoing Elective Fertility Preservation or Genetic Testing

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study of transdermal testosterone gel to improve ovarian response in women with low ovarian reserve and androgen receptor polymorphism undergoing fertility treatment

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of testosterone gel treatment for women with low ovarian reserve and androgen receptor polymorphism undergoing fertility treatment

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effect of Ovarian Stimulation Intensity Using Clomifene Citrate and Follitropin Alfa in Women with Infertility and Suboptimal Response

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

Glossary

  • Ganirelix: A gonadotropin-releasing hormone (GnRH) antagonist used to prevent premature LH surges in fertility treatments.
  • Controlled Ovarian Stimulation: A medical procedure used in fertility treatments to stimulate the ovaries to produce multiple eggs.
  • In Vitro Fertilization (IVF): A fertility treatment where eggs are fertilized by sperm outside the body in a laboratory setting.
  • Luteinizing Hormone (LH): A hormone produced by the pituitary gland that plays a crucial role in ovulation and the menstrual cycle.
  • Oocyte: An immature egg cell in the ovary.
  • Polycystic Ovary Syndrome (PCOS): A hormonal disorder common among women of reproductive age, characterized by irregular menstrual periods and elevated androgen levels.
  • Follicle-Stimulating Hormone (FSH): A hormone that stimulates the growth of ovarian follicles in women and sperm production in men.
  • Embryo Transfer: The process of placing a fertilized egg or embryo into a woman's uterus as part of IVF treatment.
  • Ovarian Reserve: The capacity of the ovary to provide egg cells capable of fertilization resulting in a healthy and successful pregnancy.
  • Intracytoplasmic Sperm Injection (ICSI): A specialized form of IVF where a single sperm is injected directly into an egg.

References

  1. https://clinicaltrials.gov/study/NCT00988260
  2. https://clinicaltrials.gov/study/NCT05751252
  3. https://clinicaltrials.gov/study/NCT00780858
  4. https://clinicaltrials.gov/study/NCT03051087
  5. https://clinicaltrials.gov/study/NCT01304511
  6. https://clinicaltrials.gov/study/NCT02796105
  7. https://clinicaltrials.gov/study/NCT01614067
  8. https://clinicaltrials.gov/study/NCT00725491
  9. https://clinicaltrials.gov/study/NCT00461422
  10. https://clinicaltrials.gov/study/NCT05994378